If you ever get discouraged feeling that nothing impactful is being done to improve Type 1 diabetes at the point of care (getting doctors on board, etc.), have a look at the Helmsley Charitable Trust. I too was pretty unfamiliar with their efforts until recent conversations on my conference tour through Orlando.
Since April of 2009, Helmsley has begun a multi-million dollar Type 1 Diabetes program that consists of four parts: a research consortium, a…
Read more »
Get ready for a slew of diabetes news announcements, because the ADA’s huge annual conference starts today!
I’ll be on an airplane pretty much all day (Friday) heading out to Orlando to cover this conference live, although I must warn you: it’s quite overwhelming. Running around the 450,000 square-foot convention center trying to see every diabetes company represented in the enormous exhibit halls while hundreds of symposia and other talk sessions are happening simultaneously is…
Read more »
By
AmyT on
April 16, 2010
If you can still get excited about diabetes research headlines, then here’s some exciting news coming out of Cambridge, Mass, this week: Tolerx, a life sciences company, has reported they are in Phase 3 clinical trials for a new treatment of type 1 diabetes. If everything goes to plan, a representative of the company says, Tolerx could launch the first-ever offering approved by the FDA to treat the cause of type 1 diabetes. Pretty cool!…
Read more »
The high-powered diabetic cycling group Team Type 1 has once again pulled off a jaw-dropping feat: they’ve somehow caught the attention of 23andMe, one of just three celeb-status companies in the world offering “personal genomics services” — they scan people’s DNA for details on their ancestry and individual health risks — and convinced them to launch a probe into Type 1 and Type 2 diabetes.
This research could provide unprecedented insights into the genes that…
Read more »
